The 2017 American Thoracic Society (ATS) International Conference was held in Washington, DC, May 19–24, 2017. As a leading meeting in respiratory medicine, dedicated to advancing the clinical and scientific understanding of pulmonary diseases, critical illnesses, and sleep-related breathing disorders, the ATS Conference attracts thousands of participants from around the world. The 2017 ATS conference featured 6700 original research projects, 500 sessions, and 800 speakers. In this activity, 2 experts summarize the key learnings on COPD from this year’s conference.
Find the latest continuing medical courses in the managed care of adult patients. These activities are designed to meet the educational needs of health care professionals who are involved with the care of adult patients.
Severe Asthma and the Primary Care Provider: Identifying Patients and Coordinating Multidisciplinary CareFormat: Webcast
This CME-accredited Through Your Patient’s EyesTM program is intended for primary care providers and other clinicians who manage patients with asthma. This educational activity has been designed to highlight issues faced by people living with asthma, including patients’ perspectives on the burdens of severe disease, difficulties related to suboptimal health literacy, and potential hurdles that can arise in busy healthcare practices. Specialist and primary care faculty discuss practical advice on overcoming these challenges, how to best coordinate multidisciplinary care, and actionable recommendations on identifying, comprehensively assessing, and longitudinally managing patients with severe asthma. As a result, clinician learners will be better prepared to engage and educate their patients with severe asthma, while improving long-term outcomes through personalized evidence-based care.
An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Conference Reporter from AD/PD™ 2017Format: Conference Reporter
The Alzheimer’s & Parkinson’s Diseases (AD/PD™) 13th International Conference was held in Vienna, Austria, March 29 to April 2, 2017. The conference attracts international medical and scientific professionals worldwide and is at the forefront of unraveling the mechanisms and improving the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD). In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.
An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Report from AAIC 2016Format: Medical Meeting Reporter
The Alzheimer's Association International Conference® 2016 (AAIC®) annual meeting was held in Toronto, Canada, July 22-28, 2016. AAIC is the world's largest forum for the dementia research community. Researchers, clinicians, care providers, and students from more than 70 countries gather at AAIC to network and discuss the latest dementia study results, theories, and discoveries. In this activity, 2 experts summarize the key learnings from this year’s conference.
The pathophysiology of Alzheimer’s disease (AD) involves both amyloid and tau proteins; the exploration of the respective roles of these proteins in neuronal loss and neurodegeneration has important implications for future therapeutic interventions. PET imaging of amyloid and tau plays a critical role in understanding neurodegeneration patterns and clinical manifestations of AD.
An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Report From CTAD 2016Format: Medical Meeting Reporter
The 9th meeting of Clinical Trials on Alzheimer’s Disease (CTAD) was held in San Diego, California, December 8-10, 2016. CTAD has become one of the most important scientific meetings in the Alzheimer’s disease (AD) area. It brings together today’s global leaders in AD to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of AD treatments. In this activity, 2 experts summarize the key learnings from this year’s conference.
Alzheimer’s Disease in Primary Care: The Significance of Early Detection, Diagnosis, and InterventionFormat: Webcast
The field of Alzheimer’s disease (AD) is undergoing a profound and rapid change: clinical trials have been redesigned to focus on individuals in the earliest stages of the disease and are including more sensitive measurement tools to better capture changes in cognition and other outcomes. Trial participants undergo PET imaging for amyloid load as a hallmark for dementia, as well as genetic testing to determine likelihood of disease progression and response to therapeutic intervention. Large national and international registries have been established to capture those at risk and to follow their development of cognitive changes longitudinally. Understanding that the disease process starts at least a decade or more before the onset of symptoms has prompted the development of therapeutic interventions acting very early in the disease cascade. For all these reasons, recognizing and diagnosing AD early offers affected individuals and their caregivers the best chance for care planning, access to available symptomatic treatment and community resources, as well as involvement with clinical trials and access to new therapies when they become available. Primary care clinicians play a pivotal role in the early recognition of cognitive impairment in their patients.
Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with TolerabilityFormat: Webcast
Effective treatment of major depressive disorder with antidepressants is currently limited by factors that affect treatment compliance, including delay in onset of therapeutic effects and, often, intolerable side-effects. Recent data suggest that use of antidepressant combinations with different mechanisms of action may be a better first-line strategy prior to augmentation with other drug classes. The rationale for this approach is that combining multiple pharmacological actions affecting multiple monoamine targets produces greater efficacy. The latest data on multimodal therapies indicate shorter onset of therapeutic effects and improved tolerability. By modulating multiple receptors and neurotransmitter systems, it is hoped that these new agents may also treat some of the associated symptoms of major depressive disorder, such as anxiety and cognitive dysfunction.